Basic Information
Foscan
Regulatory Information
EMEA/H/C/000318
Authorised
October 24, 2001
18
April 18, 2016
Company Information
Germany
Otto-Schott-Str. 15 07745 Jena
biolitec Pharma Ltd.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Foscan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Foscan.